Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Learn more about:
Related Clinical Trial
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule Optimising Molecular Radionuclide Therapy Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer Function Integrity of Neck Anatomy in Thyroid Surgery An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System Evaluation of a New CZT System Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Modified Cormack Lehane Scores Evaluated by Laryngoscopy During Awake Versus Under General Anesthesia Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain A Study Into the Effect of Seprafilm in Open Total Thyroidectomy Lenvatinib and Pembrolizumab in DTC Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Influence of Thyroid Hormones on the Woundhealing Process ctDNA in Patients With Thyroid Nodules Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine Trial of LBH589 in Metastatic Thyroid Cancer Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma Thyroid Cancer and Sunitinib Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Lipid Metabolic Status in Thyroid Carcinoma

Brief Title

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Official Title

A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Brief Summary

      This phase I trial studies the side effects and best dose of cabozantinib S-malate in
      treating younger patients with solid tumors that have come back or no longer respond to
      treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth.

Detailed Description


      I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of XL184
      (cabozantinib) (cabozantinib S-malate) administered orally to children with refractory solid
      tumors including central nervous system (CNS) tumors.

      II. To define and describe the toxicities of XL184 (cabozantinib) administered on this

      III. To characterize the pharmacokinetics of XL184 (cabozantinib) in children with refractory
      solid tumors.


      I. To preliminarily define the antitumor activity of XL184 (cabozantinib) within the confines
      of a phase 1 study.

      II. To assess the biologic activity of XL184 (cabozantinib). III. To assess the biomarker
      response (carcinoembryonic antigen [CEA] and calcitonin) in patients with medullary thyroid
      cancer treated with XL184.

      IV. To evaluate overall survival from study entry through a five-year follow-up period.

      OUTLINE: This is a dose-escalation study. (Complete as of 4/16/2014)

      Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-28. Courses
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days, 6 months, and then
      annually for up to 60 months.

Study Phase

Phase 1

Study Type


Primary Outcome

Maximum tolerated dose (MTD) and/or recommended phase 2 dose of cabozantinib S-malate

Secondary Outcome

 Pharmacokinetic (PK) parameters of cabozantinib S-malate including systemic exposure and drug clearance


Recurrent Malignant Solid Neoplasm


Cabozantinib S-malate

Study Arms / Comparison Groups

 Treatment (cabozantinib S-malate)
Description:  Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 14, 2012

Completion Date

December 31, 2019

Primary Completion Date

December 31, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have a body surface area >= 0.44 m^2 when enrolling on dose level -1;
             patients must have a body surface area >= 0.35 m^2 when enrolling on dose level 1, 2,
             or 3

          -  PART A: Patients with relapsed or refractory solid tumors (excluding medullary thyroid
             cancer) including CNS tumors and malignant melanoma are eligible; patients must have
             had histologic verification of malignancy at original diagnosis or relapse except in
             patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with
             pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers
             including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)

          -  Part B: Patients with medullary thyroid cancer (MTC), with or without bone marrow
             involvement, will be eligible for Part B; these patients will be enrolled at dose
             level 2, the recommended phase 2 dose determined in the dose escalation part of the

          -  Patients must have either measurable or evaluable disease

          -  Patient's current disease state must be one for which there is no known curative
             therapy or therapy proven to prolong survival with an acceptable quality of life

          -  Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16
             years of age

               -  Note: neurologic deficits in patients with CNS tumors must have been relatively
                  stable for at least 7 days prior to study enrollment; patients who are unable to
                  walk because of paralysis, but who are up in a wheelchair, will be considered
                  ambulatory for the purpose of assessing the performance score

          -  Patients must have fully recovered from the acute toxic effects of all prior
             anti-cancer chemotherapy:

               -  Myelosuppressive chemotherapy: at least 21 days after the last dose of
                  myelosuppressive chemotherapy (42 days if prior nitrosourea)

               -  Hematopoietic growth factors: at least 14 days after the last dose of a
                  long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth
                  factor; for agents that have known adverse events occurring beyond 7 days after
                  administration, this period must be extended beyond the time during which adverse
                  events are known to occur; the duration of this interval must be discussed with
                  the study chair

               -  Biologic (anti-neoplastic agent): at least 7 days after the last dose of a
                  biologic agent; for agents that have known adverse events occurring beyond 7 days
                  after administration, this period must be extended beyond the time during which
                  adverse events are known to occur; the duration of this interval must be
                  discussed with the study chair

               -  Immunotherapy: at least 42 days after the completion of any type of
                  immunotherapy, e.g. tumor vaccines

               -  Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose
                  of a monoclonal antibody

               -  Radiation therapy (XRT): at least 14 days after local palliative XRT (small
                  port); at least 150 days must have elapsed if prior total-body irradiation (TBI),
                  craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have
                  elapsed if other substantial bone marrow (BM) radiation

               -  Stem cell infusion without TBI: no evidence of active graft versus (vs.) host
                  disease and at least 56 days must have elapsed after transplant or stem cell

          -  For patients with solid tumors without known bone marrow involvement:

          -  Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

          -  Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
             platelet transfusions for at least 7 days prior to enrollment)

          -  Patients with known bone marrow metastatic disease will be eligible for study provided
             they meet the blood counts (may receive transfusions provided they are not known to be
             refractory to red cell or platelet transfusions); these patients will not be evaluable
             for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor
             must be evaluable for hematologic toxicity in the dose-escalation part of the study;
             if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled
             must be evaluable for hematologic toxicity

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
             ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

               -  2 to < 6 years: 0.8 mg/dL

               -  6 to < 10 years: 1 mg/dL

               -  10 to < 13 years: 1.2 mg/dL

               -  13 to < 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female)

               -  >= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female)

          -  Urine protein: =< 30 mg/dl in urinalysis or =< 1+ on dipstick, unless quantitative
             protein is < 1000 mg in a 24 hour (h) urine sample

          -  Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110
             U/L; for the purpose of this study, the ULN for SGPT is 45 U/L

          -  Serum albumin >= 2.8 g/dL

          -  Prothrombin time (PT) and international normalized ratio (INR) =< 1.5 x ULN

          -  Serum amylase =< 1.5 x ULN

          -  Serum lipase =< 1.5 x ULN

          -  A blood pressure (BP) =< the 95th percentile for age, height, and gender, and not
             receiving medication for treatment of hypertension; please note that 3 serial blood
             pressures should be obtained and averaged to determine baseline BP

          -  Central nervous system function defined as: patients with seizure disorder may be
             enrolled if receiving non-enzyme inducing anticonvulsants and well controlled

          -  No history of congenital prolonged corrected QT interval (QTc) syndrome, New York
             Heart Association (NYHA) class III or IV congestive heart failure (CHF)

          -  No clinically significant cardiac arrhythmias, stroke or myocardial infarction within
             6 months prior to enrollment

          -  QTc =< 480 msec; Note: patients with grade 1 prolonged QTc (450-480 msec) at the time
             of study enrollment should have correctable causes of prolonged QTc addressed if
             possible (i.e. electrolytes, medications)

          -  All patients and/or their parents or legally authorized representatives must sign a
             written informed consent; assent, when appropriate, will be obtained according to
             institutional guidelines

          -  Archival tumor tissue slides from either initial diagnosis or relapse must be sent; if
             tumor tissue is unavailable, the study chair must be notified prior to enrollment

        Exclusion Criteria:

          -  Pregnant or breast-feeding women will not be entered on this study; pregnancy tests
             must be obtained in girls who are post-menarchal; males or females of reproductive
             potential may not participate unless they have agreed to use two methods of birth
             control - a medically accepted barrier method of contraceptive method (e.g., male or
             female condom) and a second effective contraceptive method of birth control - during
             protocol therapy and for at least 4 months after the last dose of XL184; abstinence is
             an acceptable method of birth control

          -  Patients receiving corticosteroids who have not been on a stable or decreasing dose of
             corticosteroid for at least 7 days prior to enrollment are not eligible

          -  Patients who are currently receiving another investigational drug are not eligible

          -  Patients who are currently receiving other anti-cancer agents are not eligible

          -  Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
             graft-versus-host disease post bone marrow transplant are not eligible for this trial

          -  Patients must not be receiving any of the following potent cytochrome P450 family 3,
             subfamily A, polypeptide 4 cytochrome (CYP3A4) inducers or inhibitors: erythromycin,
             clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St.
             John's wort

          -  Patients who are receiving systemic treatment anticoagulation are not eligible;
             patients receiving prophylactic systemic anticoagulation will be allowed as long as
             eligibility PT/INR requirements are met

          -  Patients must not have received enzyme-inducing anticonvulsants within 14 days prior
             to enrollment

          -  Patients who are receiving drugs that prolong QTc are not eligible

          -  Patients must be able to swallow intact tablets; patients who cannot swallow intact
             tablets are not eligible

          -  Patients with active bleeding are not eligible; specifically, no clinically
             significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or
             fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary
             hemorrhage for 3 months prior to enrollment

          -  Patients with evidence of an acute intracranial or intratumoral hemorrhage on computed
             tomography (CT) or magnetic resonance imaging (MRI) are not eligible (patients with
             evidence of resolving hemorrhage will be eligible)

          -  Patients who have had or are planning to have the following invasive procedures are
             not eligible:

               -  Major surgical procedure, laparoscopic procedure, open biopsy or significant
                  traumatic injury within 28 days prior to enrollment

               -  Central line placement or subcutaneous port placement is not considered major
                  surgery but must be placed at least 3 days prior to enrollment for external lines
                  (e.g. Hickman or Broviac) and at least 7 days prior to enrollment for
                  subcutaneous port

               -  Core biopsy within 7 days prior to enrollment

               -  Fine needle aspirate within 7 days prior to enrollment

               -  Surgical or other wounds must be adequately healed prior to enrollment

          -  Patients on antihypertensive therapy for control of blood pressure at the time of
             enrollment are not eligible

          -  Patients with any medical or surgical conditions that would interfere with
             gastrointestinal absorption of this oral agent are not eligible

          -  Patients who have an uncontrolled infection are not eligible

          -  Patients who have received a prior solid organ transplantation are not eligible

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study are not eligible




2 Years - 18 Years

Accepts Healthy Volunteers



Meredith K Chuk, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

National Cancer Institute (NCI)

Study Sponsor

Meredith K Chuk, Principal Investigator, COG Phase I Consortium

Verification Date

April 2020